This March is Colorectal Cancer Awareness Month, and Colorectal Cancer Canada is calling on health authorities across the country to lower the screening age to 45 to help detect cancer earlier and improve outcomes. Learn more at: colorectalcancercanada.com/screenat45
#colorectalcancerawareness #crcm

📣 External Seminar

🎙️ Rafael J. Argüello, CNRS Assistant Researcher at CIML, will talk about novel single-cell technologies 🧪

📍 CRCM - Library
📆 March 3, 2026
🕘 11:15 AM

@ciml.bsky.social

#CRCM #Seminar #CancerResearch

📰 La Provence highlights a major project in Marseille:
the development of France’s largest research lab dedicated to pancreatic cancer, led by the CRCM.
🔬 2,500+ m²
🌍 90 researchers
🎯 Earlier detection, better treatments
#PancreaticCancer #Research #CRCM #Marseille #Science #LaProvence @univ-amu.fr

📣 External Seminar

🎙️ May Morris, CNRS Research Director at the Max Mousseron Institute of Biomolecules (IBMM) in Montpellier, will talk about fluorescent biosensors 🧪

📍 CRCM - Library
📆 January 20, 2026
🕘 11 AM

#CRCM #Seminar #DrugDiscovery #CancerResearch

📣 External Seminar

🎙️ Russel Rockne, Associate Professor in the Department of Computational and Quantitative Medicine at City of Hope, will talk about Mathematical Oncology !

📍 Paoli-Calmettes Institute - Amphitheater IPC2
📆 December 18, 2025
🕘 10 AM

#CRCM #Seminar #Mathematics #CancerResearch

🧬 Il est temps de finaliser votre abstract !
👉 Date limite : 14 novembre 2025 (inclus, à minuit CEST)
📩 Les abstracts sélectionnés seront annoncés en décembre 2025.
🎓 Symposium du CRCM — 4–6 février 2026, Marseille
#CRCM #CancerResearch #CRCMSymposium2026

🎓 SAVE THE DATE – CRCM Symposium 2026
📅 Feb 4–6, 2026
📍 Palais du Pharo, Marseille
The first CRCM Symposium will gather scientists to discuss key advances in cancer research, from cell communication to innovative therapies.
👉 More here: crcm-symposium.com
#CRCM #CancerResearch #Symposium

Met'Connect was present at the 6th Metabolism&Cancer meeting. Thank you to the Canceropole PACA for their support

@canceropolesud.bsky.social

#C3M #CRCM #universitecotedazur #universitéAixMarseille #recherche #congress

The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active - Nature Communications Targeting histone deacetylases (HDACs) alone has shown limited success in solid tumours. Here, authors report that the HDAC1/2 inhibitor romidepsin confers responsiveness to receptor tyrosine kinase inhibitors, with enhanced therapeutic effects in models of hepatocellular carcinoma, leading to tumour regression and an immune-stimulatory profile.

The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active
www.nature.com/articles/s41...

Fantastic new paper from Flavio Maina, Celia Sequera, Margherita Grattarola and colleagues at the @crcm.bsky.social

#CancerResearch, #CRCM, #LiverCancer